STAT+: From Revolution Medicines, more strong data on KRAS drug and a glimpse of a ‘novel class’ beyond it
A company that is changing the outlook on pancreatic cancer has more promising data for treatments near-term and for a generation beyond.
STAT+: At AACR, more strong results for Revolution Medicine’s KRAS drug, plus assurance from NCI’s director
At AACR, Revolution Medicines presented more eye-catching data about its KRAS-targeting treatment, and Anthony Letai declared the state of cancer research steady.
STAT+: Key GOP senators push back on Trump’s plan to cut NIH, reorganize HHS
Lawmakers seem poised to reject cuts to biomedical research and public health spending for a second straight year.
STAT+: Trump’s plan to give seniors cheaper obesity drugs in Medicare hits a snag
Health insurers would likely face a financial strain by participating in the Medicare pilot.
Breaking Down the U.S. Global Health Budget by Program Area
The U.S. government is the largest donor to global health in the world. This fact sheet breaks down the U.S. global health budget by program area: HIV/PEPFAR; tuberculosis; malaria/the President's…
Medicaid Waiver Tracker: Approved and Pending Section 1115 Waivers by State
Section 1115 Medicaid waivers can allow states to test new approaches in Medicaid that differ from what is required by federal law. This page tracks approved and pending waiver provisions…
STAT+: RFK Jr. to face four GOP doctors at Senate hearings
We'll be zeroed in on Kennedy's exchanges with one doc in particular: Bill Cassidy.
A criminal sentence for OxyContin maker Purdue Pharma clears the way for completing its settlement
A judge is expected to sentence OxyContin maker Purdue Pharma to forfeit $225 million to the Justice Department on Tuesday, clearing the way for the company to finalize a settlement…
STAT+: Kelonia Therapeutics’ road from floundering to $3 billion
BioAge bets on inflammation, a short Pfizer career, and more biotech news from The Readout
STAT+: Pharmalittle: We’re reading about a Purdue Pharma settlement, a setback for Merck and Eisai, and more
A U.S. judge is expected to direct Purdue Pharma to forfeit $225 million to the Justice Department, clearing the way for a massive settlement